Profile data is unavailable for this security.
About the company
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
- Revenue in CHF (TTM)157.63m
- Net income in CHF10.45m
- Incorporated2002
- Employees147.00
- LocationBasilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
- Phone+41 616061111
- Fax+41 616061112
- Websitehttps://www.basilea.com/
More ▼
Mergers & acquisitions
| Acquired company | BSLN:SWX since announced | Transaction value |
|---|---|---|
| Spexis AG-Preclinical Antibiotics Program | 23.21% | 2.35m |
Data delayed at least 15 minutes, as of May 24 2024 14:04 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals Holding AG | 103.38m | 54.78m | 119.94m | 46.00 | -- | 1.78 | -- | 1.16 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
| Molecular Partners AG | 6.73m | -58.53m | 124.17m | 168.00 | -- | 0.6601 | -- | 18.46 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Newron Pharmaceuticals SpA | 8.95m | -16.04m | 181.83m | 23.00 | -- | -- | -- | 20.31 | -0.8988 | -0.8988 | 0.5018 | -1.66 | 0.2873 | -- | 4.57 | 389,307.50 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Xlife Sciences AG | 988.44k | 14.88m | 193.91m | 17.00 | 27.92 | 0.709 | 7.66 | 196.18 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Kuros Biosciences AG | 33.56m | -13.73m | 295.01m | 80.00 | -- | 5.18 | -- | 8.79 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 141.42m | -55.88m | 417.24m | 938.00 | -- | -- | -- | 2.95 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 581.44m | 147.00 | 50.37 | -- | 48.25 | 3.69 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 321.16m | -50.86m | 1.07bn | 1.20k | -- | 2.83 | -- | 3.33 | -1.54 | -1.54 | 9.70 | 11.43 | 0.5137 | 2.31 | 5.08 | 267,189.00 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 95.62m | 1.13m | 1.27bn | 325.00 | 1,030.29 | 2.76 | 82.47 | 13.31 | 0.0704 | 0.0704 | 5.93 | 26.28 | 0.1473 | 3.06 | 2.88 | 294,227.10 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| BB BIOTECH AG | 270.74m | 307.74m | 2.29bn | -- | 7.37 | 0.9178 | -- | 8.47 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
Data as of May 24 2024. Currency figures normalised to Basilea Pharmaceutica AG Allschwil's reporting currency: Swiss Franc CHF
26.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Black Creek Investment Management, Inc.as of 04 May 2023 | 663.67k | 5.07% |
| CI Investments, Inc.as of 31 Dec 2022 | 642.07k | 4.90% |
| The Vanguard Group, Inc.as of 09 May 2024 | 447.02k | 3.41% |
| Braginsky Family Office AGas of 13 Sep 2023 | 391.68k | 2.99% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 31 Mar 2024 | 332.72k | 2.54% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 263.88k | 2.01% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 219.10k | 1.67% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 190.03k | 1.45% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 182.98k | 1.40% |
| BlackRock Fund Advisorsas of 09 May 2024 | 171.74k | 1.31% |
More ▼
Data from 13 Sep 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
